End-of-day quote
Shanghai S.E.
06:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
26.91
CNY
|
-1.75%
|
|
-10.66%
|
-34.75%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
17,077
|
11,143
|
-
|
-
|
Enterprise Value (EV)
1 |
17,077
|
11,143
|
11,143
|
11,143
|
P/E ratio
|
-42.5
x
|
-538
x
|
19.5
x
|
8.38
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
7.48
x
|
4.49
x
|
2.52
x
|
EV / Revenue
|
-
|
7.48
x
|
4.49
x
|
2.52
x
|
EV / EBITDA
|
-
|
52.1
x
|
13.9
x
|
6.1
x
|
EV / FCF
|
-
|
52.4
x
|
22.6
x
|
6.77
x
|
FCF Yield
|
-
|
1.91%
|
4.42%
|
14.8%
|
Price to Book
|
-
|
8.31
x
|
5.68
x
|
3.24
x
|
Nbr of stocks (in thousands)
|
414,080
|
414,080
|
-
|
-
|
Reference price
2 |
41.24
|
26.91
|
26.91
|
26.91
|
Announcement Date
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.7
|
-
|
1,490
|
2,484
|
4,415
|
EBITDA
1 |
-969.4
|
-
|
214
|
803.5
|
1,828
|
EBIT
1 |
-1,024
|
-
|
142.5
|
717
|
1,739
|
Operating Margin
|
-146,269.71%
|
-
|
9.56%
|
28.87%
|
39.39%
|
Earnings before Tax (EBT)
1 |
-1,023
|
-
|
-22
|
672
|
1,564
|
Net income
1 |
-1,023
|
-401.3
|
-22
|
571
|
1,329
|
Net margin
|
-146,088.83%
|
-
|
-1.48%
|
22.99%
|
30.1%
|
EPS
2 |
-
|
-0.9700
|
-0.0500
|
1.380
|
3.210
|
Free Cash Flow
1 |
-
|
-
|
212.6
|
492.4
|
1,646
|
FCF margin
|
-
|
-
|
14.27%
|
19.83%
|
37.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
99.32%
|
61.29%
|
90.04%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
86.24%
|
123.85%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
213
|
492
|
1,646
|
ROE (net income / shareholders' equity)
|
-
|
-
|
8.3%
|
31.8%
|
42.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
5.25%
|
18.3%
|
29.1%
|
Assets
1 |
-
|
-
|
-419
|
3,120
|
4,567
|
Book Value Per Share
2 |
1.780
|
-
|
3.240
|
4.740
|
8.300
|
Cash Flow per Share
2 |
-1.690
|
-
|
-0.9300
|
1.460
|
2.420
|
Capex
1 |
-
|
-
|
116
|
128
|
156
|
Capex / Sales
|
-
|
-
|
7.75%
|
5.15%
|
3.52%
|
Announcement Date
|
2/27/20
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
26.91
CNY Average target price
54
CNY Spread / Average Target +100.67% Consensus |
1st Jan change
|
Capi.
|
---|
| -34.75% | 1.54B | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.69% | 21.78B | | -10.60% | 18.09B | | -41.25% | 16.72B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|